Gastrointestinal cancer: Recent developments in medical oncology

European Journal of Surgical Oncology

Volumn 31, Issue 5, 2005, Pages 453-460

  Chong, G ^a   Cunningham, David ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Monoclonal antibody; Multidisciplinary; Neoadjuvant chemotherapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; UFT; VASCULOTROPIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ERUPTION; DRUG TARGETING; DRUG USE; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MEDICAL LITERATURE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOMES RESEARCH; PANCREAS CANCER; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PREOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; STOMACH CANCER; STOMATITIS;

COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS;

EID: 19444377245     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.02.026     Document Type: Review

References (46)

1. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002;359:1727-33.
2. D.P. Kelsen R. Ginsberg T.F. Pajak D.G. Sheahan L. Gunderson J. Mortimer et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 1998 1979-1984
3. J. Chipponi M. Huguier D. Pezet N. Basso J.M. Hay P. Quandalle et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer Am J Surg 187 2004 440-445
4. B. Neri G. Cini F. Andreoli B. Boffi D. Francesconi R. Mazzanti et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up Br J Cancer 84 2001 878-880
5. H.M. Chang K.H. Jung T.Y. Kim W.S. Kim H.K. Yang K.U. Lee et al. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer Ann Oncol 13 2002 1779-1785
6. J.S. Macdonald T.R. Fleming R.F. Peterson J.L. Berenberg S. McClure R.A. Chapman et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study Ann Surg Oncol 2 1995 488-494
7. M. Lise D. Nitti A. Marchet T. Sahmoud M. Buyse N. Duez et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer J Clin Oncol 13 1995 2757-2763
8. E. Mari I. Floriani A. Tinazzi A. Buda M. Belfiglio M. Valentini et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) Ann Oncol 11 2000 837-843
9. J.S. Macdonald S.R. Smalley J. Benedetti S.A. Hundahl N.C. Estes G.N. Stemmermann et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725-730
10. J.S. Macdonald S.R. Smalley J. Benedetti N. Estes D.G. Haller J. Ajani et al. Postoperative combined radiation and chemotherapy improves disease-free survival and overall survival in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 Proc GI Can Symp 1 2004 [Abstract 6]
11. W. Allum D. Cunningham S. Weeden Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) Proc Am Soc Clin Oncol 22 2003 [Abstract 998]
12. B. Glimelius K. Ekstrom K. Hoffman W. Graf P.O. Sjoden U. Haglund et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 1997 163-168
13. P. Ross M. Nicolson D. Cunningham J. Valle M. Seymour P. Harper et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 2002 1996-2004
14. J.L. Van Laethem A. Demols F. Gay M.T. Closon M. Collette M. Polus et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: A phase II study Int J Radiat Oncol Biol Phys 56 2003 974-980
15. V.K. Mehta J.C. Poen J.M. Ford H.A. Oberhelman M.A. Vierra A.J. Bastidas et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer Am J Clin Oncol 24 2001 155-159
16. J.H. Klinkenbijl J. Jeekel T. Sahmoud R. van Pel M.L. Couvreur C.H. Veenhof et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776-782
17. K.E. Bakkevold B. Arnesjo O. Dahl B. Kambestad Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study Eur J Cancer 29A 1993 698-703
18. J.P. Neoptolemos D.D. Stocken H. Friess C. Bassi J.A. Dunn H. Hickey et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200-1210
19. J.P. Neoptolemos J.A. Dunn D.D. Stocken J. Almond K. Link H. Beger et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial Lancet 358 2001 1576-1585
20. H.A. Burris III M.J. Moore J. Andersen M.R. Green M.L. Rothenberg M.R. Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413
21. G.P. Stathopoulos K. Syrigos A. Polyzos G. Fountzilas S.K. Rigatos N. Ziras et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study Ann Oncol 15 2004 224-229
22. W. Scheithauer B. Schull H. Ulrich-Pur K. Schmid M. Raderer K. Haider et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial Ann Oncol 14 2003 97-104
23. C. Louvet T. Andre G. Lledo P. Hammel H. Bleiberg C. Bouleuc et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study J Clin Oncol 20 2002 1512-1518
24. C.G. Moertel T.R. Fleming J.S. Macdonald D.G. Haller J.A. Laurie C.M. Tangen et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report Ann Intern Med 122 1995 321-326
25. M.J. O'Connell J.A. Mailliard M.J. Kahn J.S. Macdonald D.G. Haller R.J. Mayer et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer J Clin Oncol 15 1997 246-250
26. T. Hickish C. Boni J. Tabernero P. Clingan G. Colucci M. Nowacki et al. Oxaliplatin/5-fluorouracil/leucovorin in stage II and III colon cancer: updated results of the international randomized 'MOSAIC' trial Proc Am Soc Clin Oncol GI Symp 2004 [Abstract 211]
27. T. Andre C. Boni L. Mounedji-Boudiaf M. Navarro J. Tabernero T. Hickish et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343-2351
28. W. Scheithauer J. McKendrick S. Begbie M. Borner W.I. Burns H.A. Burris et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial Ann Oncol 14 2003 1735-1743
29. J. Cassidy W. Scheithauer J. McKendrick M. Kroning M. Nowacki J. Seitz et al. Capecitabine vs bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial Proc Am Soc Clin Oncol 22 2004 [Abstract 3509]
30. R.J. Heald R.D. Ryall Recurrence and survival after total mesorectal excision for rectal cancer Lancet 1 1986 1479-1482
31. G. Brown C.J. Richards R.G. Newcombe N.S. Dallimore A.G. Radcliffe D.P. Carey et al. Rectal carcinoma: Thin-section MR imaging for staging in 28 patients Radiology 211 1999 215-222
32. J. Feliu J. Calvilio A. Escribano J. de Castro M.E. Sanchez A. Mata et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy Ann Oncol 13 2002 730-736
33. J.P. Gerard O. Chapet C. Nemoz P. Romestaing F. Mornex R. Coquard et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial J Clin Oncol 21 2003 1119-1124
34. R. Sauer H. Becker W. Hohenberger C. Rodel C. Wittekind R. Fietkau et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731-1740
35. I. Chau D. Cunningham D. Tait G. Brown N. Tebbutt M. Hill et al. Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief Proc Am Soc Clin Oncol 22 2003 [Abstract 1087]
36. L.B. Saltz J.V. Cox C. Blanke L.S. Rosen L. Fehrenbacher M.J. Moore et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905-914
37. D. Cunningham B. Glimelius A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group Semin Oncol 26 1999 6-12
38. A. De Gramont A. Figer M. Seymour M. Homerin A. Hmissi J. Cassidy et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938-2947
39. C. Tournigand T. Andre E. Achille G. Lledo M. Flesh D. Mery-Mignard et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study J Clin Oncol 2003
40. R.M. Goldberg D.J. Sargent R.F. Morton C.S. Fuchs R.K. Ramanathan S.K. Williamson et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23-30
41. R. Adam E. Avisar A. Ariche S. Giachetti D. Azoulay D. Castaing et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal Ann Surg Oncol 8 2001 347-353
42. H. Bismuth R. Adam Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy Semin Oncol 25 1998 40-46
43. H. Bismuth R. Adam F. Levi C. Farabos F. Waechter D. Castaing et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 224 1996 509-520
44. P.J. O'dwyer A.B. Benson III Epidermal growth factor receptor-targeted therapy in colorectal cancer Semin Oncol 29 2002 10-17
45. D. Cunningham Y. Humblet S. Siena D. Khayat H. Bleiberg A. Santoro et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337-345
46. H. Hurwitz L. Fehrenbacher W. Novotny T. Cartwright J. Hainsworth W. Heim et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335-2342